Abstract:Background: Neoadjuvant chemotherapy (NCT) has become an important part in the comprehensive treatment of breast cancer, patients classified with pathological complete remission (pCR) after NCT have superior outcome. A single center, prospective phase II study was initiated to evaluate the activity and safety of non-anthracycline-containing weekly PCb regimen in NCT for breast cancer, which may help our further clinical usage and research.Materials and Methods: Eligible patients with clinical stage IIA∼IIIC breast cancer were assigned to receive four cycles of PCb with the dose of P (Paclitaxel) 80mg/m2 and Cb (Carboplatin) AUC=2, given day 1, day 8 and day 15, out of every 4 weeks. Clinical response and extent of residual disease in breast and axillary lymph nodes (ALN) in surgical removed sample were assessed after completion of NCT. pCR was defined as no invasive cancer in breast and axillary. Estrogen(ER), Progesterone (PR) receptor and HER2 status were detected before treatment by immunohistochemistry, HR (hormonal receptor) was defined positive as either or both ER/PR positive.Results: From Dec. 2007 to Dec. 2008, 107 breast cancer patients received weekly PCb NCT and one with bilateral breast cancer. 85.2% patients were initially diagnosed with stage III diseases, 83 patients had positive ALN confirmed by fine needle aspiration before NCT. 94.4% (102) patients have completed all of 4 cycles weekly PCb treatment. Clinical response rate was 86.1% with clinical complete remission rate 32.4%. 21 patients achieved pCR, with pCR rate 19.4%. 30 cases who had positive ALN before NCT showed negative result in the surgery specimen with ALN downstage rate 36.6%. The incidence of grade 3-4 neutropenia was 40.2% and only 1 patient was reported with febrile neutropenia. Severe thrombocytopenia and anemia occurred in 0.9% and 4.7% of patients, respectively. Peripheral neuropathy was frequent, but never severe, only 5 (4.7%) patients recorded had more than grade 1 toxicity. Patients with ER- disease had superior pCR rate than ER+ patients (32.6% vs. 9.7%, P=0.005). Patients with PR- disease had higher pCR rate than PR+ patients (30.6% vs. 10.2%, P=0.010). pCR rate was 33.3% (8/24) and 15.5% (13/84) in HER2+ and HER2- patients. Furthermore, We used ER, PR and HER2 status to construct molecular classification of breast cancer, patients classified with Luminal A (HR+/HER2-) subtype had the lowest pCR rate, which was 8.3% less than 22.2% in Luminal B (HR+/HER2+), 33.3% in triple-negative (HR-/HER2-) and 40.0% in HER2 positive (HR-/HER2+) subtype patients, P=0.017.Conclusions: Weekly PCb regimen was very active and tolerable as NCT for breast cancer. ER-, PR-, HER2+ and triple negative breast cancer were more likely to achieve pCR. This weekly PCb regimen should consider as a reasonable non-anthracycline-containing option in NCT setting of breast cancer. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 1099.

Treatment of locally advanced breast cancer with breast-conserving therapy after neoadjuvant chemotherapy: Report of 31 cases

[Feasibility of Breast Conservation Surgery after Neoadjuvant Chemotherapy for Breast Cancer].

[Breast-Conserving Therapy for Centrally Located Primary Breast Cancer].

Breast-conserving Therapy for Patients with Early Stage Breast Carcinoma

125I Brachytherapy of Locally Advanced Non-Small-cell Lung Cancer after One Cycle of First-Line Chemotherapy: a Comparison with Best Supportive Care.

Outcome of breast-conservative therapy for early-stage breast cancer: a retrospective analysis

Conservation treatment intensified with an anti-estrogen agent and CAF chemotherapy for stage I and II breast cancer

Breast-Conserving Therapy Achieves Locoregional Outcomes Comparable to Mastectomy in Women with T1-2N0 Triple-Negative Breast Cancer

Evaluation of the Curative Effect in Breast-Conserving Therapy

Clinical Analysis of Efficacy and Cosmetic Results in 234 Early Breast Cancer Patients with Breast-Conserving Treatment

[The Early Results of Breast-Conserving Therapy in Ninety-Five Patients of Primary Breast Cancer].

Breast Conserving Therapy in Stage T 1 & T 2 Breast Cancer Patients

Final Result of Non-Anthracycline Containing Weekly Paclitaxel Plus Carboplatin Regimen As Neoadjuvant Chemotherapy for Breast Cancer.

A Multicentric Prospective Study of the Effect of Neoadjuvant Chemotherapy with Cyclophosphamide,Fluorouracil and Pirarubicin on Localy Advanced Breast Cancer

Breast conservation therapy after neoadjuvant chemotherapy: Optimization of a multimodality approach

Breast Conservation Therapy Achieved Comparable Outcomes With Mastectomy In Patients With T1-2n0 Triple-Negative Breast Cancer: Analysis Of 822 Patients In A Single Institution

Effect of Neoadjuvant Chemotherapy in Treatment of Locally Advanced Breast Cancer with Cytologically Proven Axillary Node Metastases

Progression of Treatment in Locally Advanced Breast Cancer

Breast Conserving Therapy in Stage T1 & T2 Breast Cancer Patients

Oncological outcomes of post neo adjuvant chemotherapy breast conservation surgery in patients with locally advanced breast cancer

Local treatment for triple-negative breast cancer patients undergoing chemotherapy: breast-conserving surgery or total mastectomy?